Alamar Biosciences, Inc.
ALMR
$29.36
-$0.60-1.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 82.08% | 98.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 82.08% | 98.88% | |||
| Cost of Revenue | 54.45% | 72.75% | |||
| Gross Profit | 106.48% | 126.28% | |||
| SG&A Expenses | 129.23% | 107.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 78.39% | 77.33% | |||
| Operating Income | -70.88% | -44.36% | |||
| Income Before Tax | -89.26% | -172.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -87.94% | -178.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -87.94% | -178.43% | |||
| EBIT | -70.88% | -44.36% | |||
| EBITDA | -77.11% | -45.86% | |||
| EPS Basic | 63.44% | -155.68% | |||
| Normalized Basic EPS | 67.01% | -47.08% | |||
| EPS Diluted | 63.44% | -155.68% | |||
| Normalized Diluted EPS | 67.01% | -47.08% | |||
| Average Basic Shares Outstanding | 414.17% | 8.89% | |||
| Average Diluted Shares Outstanding | 414.17% | 8.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||